2022 年第三季度报告 证券代码：600613 证券简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2022 年第三季度报告 2022 年 10 月 1 / 13 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人张芝庭先生、主管会计工作负责人李发淼先生及会计机构负责人（会计主管人员） 王霞娟女士声明：保证季度报告中财务报告的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | | --- | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | | ...

Financial Performance - The company's operating revenue for 2021 was RMB 2,303,032,719, representing a 26.61% increase compared to RMB 1,819,006,691 in 2020[19]. - Net profit attributable to shareholders reached RMB 69,622,537, a significant increase of 120.41% from a loss of RMB 341,202,593 in 2020[21]. - The net profit after deducting non-recurring gains and losses was RMB 38,620,696, up 111.21% from a loss of RMB 344,510,890 in the previous year[22]. - Cash flow from operating activities increased by 85.94%, totaling RMB 184,263,469 compared to RMB 99,097,235 in 2020[19]. - Basic and diluted earnings per share were both RMB 0.13, a 120.31% increase from a loss of RMB 0.64 in 2020[20]. - The weighted average return on equity rose to 3.01%, an increase of 20.88 percentage points from -17.87% in 2020[20]. - The total assets at the end of 2021 were RMB 3,148,970,121, a 1.65% increase from RMB 3,097,971,351 at the end of 2020[19]. - The net assets attributable to shareholders increased by 2.94% to RMB 2,344,283,895 from RMB 2,277,367,601 in 2020[19]. - The company disposed of an investment subsidiary, generating an investment income of over RMB 28,100,000, contributing to the profit growth[22]. Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.8 RMB based on a total share capital of 534,071,628 shares as of December 31, 2021[4]. - The cash dividend policy is in compliance with the company's articles of association and has clear standards and ratios for distribution[200]. Risk Management - The company emphasizes that forward-looking statements regarding future plans and development strategies do not constitute a substantive commitment to investors, highlighting the importance of investment risk awareness[5]. - The company has detailed potential risks in the section discussing future development in the annual report[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[6]. - There are no violations of decision-making procedures regarding external guarantees[6]. - The company is closely monitoring industry policy changes and regulatory risks, establishing a dynamic warning mechanism to adapt to new regulations and maintain profitability[155]. Research and Development - The company continues to innovate in drug research and development, achieving multiple technological advancements and applying for national patents[36]. - Research and development expenses rose to CNY 50.95 million, reflecting a 19.06% increase from the previous year[83]. - The company holds a total of 133 patents, including 84 invention patents, enhancing its market competitiveness[80]. - The company is increasing investment in R&D for traditional Chinese medicine products, focusing on optimizing production processes and enhancing quality control standards[112]. - The company is conducting evidence-based medical research on sodium cantharidate products to explore further indications and derivative development[113]. Market Position and Strategy - The company is focusing on brand building as a systematic project to enhance its industry position and brand image[44]. - The company has a market share leading position in its core product, the sodium cantharidate series, which is a unique product in the country[68]. - The company collaborates with well-known hospitals for clinical research and technology transfer, enhancing its competitive edge in the industry[73]. - The company is actively exploring the dermatology and chronic disease segments, emphasizing the development of unique and key products to address chronic diseases and skin conditions[146]. - The company is positioned to leverage policy advantages and market demand in the pharmaceutical sector, particularly in response to the COVID-19 pandemic and related healthcare needs[110]. Corporate Governance - The company has established a robust corporate governance structure to ensure independent operations and protect shareholder rights[169]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement of one-third independence[170]. - The company has established performance evaluation standards and procedures for senior management[171]. - The company has implemented a management system for information disclosure to ensure timely and accurate information sharing with shareholders[171]. - The company respects the rights of stakeholders, including creditors and employees, to promote sustainable development[171]. Operational Efficiency - The company is committed to cost control and efficiency improvement through lean management initiatives, aiming to reduce production costs and enhance operational efficiency[150]. - The company is enhancing its internal control systems to mitigate operational risks and improve efficiency, focusing on compliance and risk prevention measures[151]. - The company has implemented online operations and remote video meetings to ensure stable product quality and market supply during the pandemic[157]. - The company is enhancing procurement management and establishing strategic inventory reserves to mitigate raw material cost pressures[159]. Employee Management - The total number of employees in the parent company and major subsidiaries is 1,371, with 7 in the parent company and 1,364 in subsidiaries[194]. - The workforce includes 514 production personnel, 115 sales personnel, 221 technical personnel, 47 financial personnel, and 474 administrative personnel[194]. - The company emphasizes performance-based salary structures, linking employee compensation to company and individual performance[195]. - Future adjustments to the salary system will consider operational results and local market conditions to enhance employee benefits[196]. - The company has implemented targeted training programs to improve employee skills and overall management levels[197].

2021 年第三季度报告 证券代码：600613 证券简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2021 年第三季度报告 2021 年 10 月 1 / 13 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | | --- | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | | 动幅度(%) | | (%) | | | 营业收入 | 547,399,983.42 ...

2021 年半年度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2021 年半年度报告 2021 年 8 月 1 / 144 2021 年半年度报告 重要提示 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，请投资 者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人张芝庭、主管会计工作负责人李发淼及会计机构负责人（会计主管人员）王霞娟 声明：保证半年度报告中财务报告的真实、准确、完整。 | 第一节 | 释义 4 | | --- | --- | | 第二节 | 公司简介和主要财务指标 5 ...

2021 年第一季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2021 年第一季度报告 2021 年 4 月 1 / 21 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | 本报告期末 | 上年度末 | 本报告期末比上年度 | | --- | --- | --- | --- | | | | | 末增减(%) | | 总资产 | 3,164,307,522.46 | 3,097,971,351.94 | 2.14 | | 归属于上市公司 | 2,293,246,742.62 | 2,277,367,601.10 | 0.70 | | 股东的净资产 | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | 经营活动产生的 | 53,017,693.53 | 14,904,611.03 | 255.71 | | ...

2021 年第一季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2021 年第一季度报告正文 2021 年 4 月 1 / 5 2021 年第一季度报告 一、 重要提示 二、 公司主要财务数据和股东变化 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度 | | --- | --- | --- | --- | | | | | 末增减(%) | | 总资产 | 3,164,307,522.46 | 3,097,971,351.94 | 2.14 | | 归属于上市公司 | 2,293,246,742.62 | 2,277,367,601.10 | 0.70 | | 股东的净资产 | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | 经营活动产生的 | 53,017,693.53 | 14,904,611.03 | 255.71 | | 现金流量净额 | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减（%） | | ...

2020 年年度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2020 年年度报告 2021 年 4 月 1 / 208 2020 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人张芝庭、主管会计工作负责人李发淼及会计机构负责人（会计主管人员）王霞娟 声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 鉴于公司2020年度经营亏损、子公司沙文生产研发基地项目建设投资资金需求量较大，公司本 年度不派发现金红利，不送红股、不以公积金转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，请投资 者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占 ...

2020 年第三季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2020 年第三季度报告 2020 年 10 月 1 / 24 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2020 年第三季度报告 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张芝庭、主管会计工作负责人李发淼及会计机构负责人（会计主管人员）王霞娟 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 24 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 3,329,466,226.78 3,556,129,011.94 -6.37 归属于上市公司 股东的净资产 2,471,920,637.76 2,616,935,698.11 -5.54 年初至报告期末 （1-9 月） 上年 ...

2020 年第三季度报告 公司代码： 600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2020 年第三季度报告正文 2020 年 10 月 1 / 7 2020 年第三季度报告 一、 重要提示 二、 公司主要财务数据和股东变化 2.1 主要财务数据 2 / 7 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 3,329,466,226.78 3,556,129,011.94 -6.37 归属于上市公司 股东的净资产 2,471,920,637.76 2,616,935,698.11 -5.54 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减(%) 经营活动产生的 现金流量净额 46,442,467.26 105,543,021.65 -56.00 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减 （%） 营业收入 1,329,402,092.59 1,420,774,426.01 -6.43 归属于上市公司 股东的净利润 -146,963,628.0 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥839,327,318.01, a decrease of 7.87% compared to ¥911,009,600.51 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥28,530,267.49, down 50.08% from ¥57,149,229.91 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,688,798.42, a decrease of 45.43% compared to ¥56,235,803.84 in the same period last year[19]. - The net cash flow from operating activities was ¥39,280,109.64, down 41.53% from ¥67,183,416.47 in the previous year[19]. - The company's basic and diluted earnings per share decreased by 45.45% to CNY 0.06 compared to the same period last year[20]. - The net profit attributable to shareholders decreased by 50.08%, amounting to a reduction of CNY 28.62 million, primarily due to decreased sales in the pharmaceutical manufacturing sector[21]. - The operating cash flow net amount decreased by 41.53%, resulting in a decline of CNY 27.90 million, attributed to reduced sales revenue in the pharmaceutical manufacturing sector[21]. - The weighted average return on net assets decreased by 1.15 percentage points to 1.08% compared to the same period last year, mainly due to the decline in sales revenue[21]. - The company experienced a 7.87% decrease in total operating revenue, amounting to a reduction of CNY 71.68 million, with a significant impact from COVID-19 on sales of cold and cough medications[20]. - The sales of cough medications dropped by 67.79%, resulting in a decrease of CNY 54.59 million due to restrictions on sales in hospitals[20]. Assets and Liabilities - The net assets attributable to shareholders at the end of the reporting period were ¥2,644,724,228.63, an increase of 1.06% from ¥2,616,935,698.11 at the end of the previous year[19]. - Total assets at the end of the reporting period were ¥3,493,802,463.57, a decrease of 1.75% from ¥3,556,129,011.94 at the end of the previous year[19]. - The company's cash and cash equivalents increased to ¥512,790,239.83, representing 14.68% of total assets, up 42.35% from ¥360,220,096.71 last year[52]. - Accounts receivable decreased significantly by 77.07% to ¥23,030,023.37, down from ¥100,416,203.88, which accounted for 0.66% of total assets[52]. - The company reported a substantial increase in construction in progress, rising by 57.01% to ¥490,630,263.86, compared to ¥312,477,377.68 in the previous year, representing 14.04% of total assets[53]. - Short-term borrowings decreased by 67.63% to ¥32,719,000 from ¥101,080,000, which accounted for 0.94% of total liabilities[54]. - The company’s long-term borrowings increased significantly by 1,973.33% to ¥311,000,000 from ¥15,000,000, representing 8.90% of total liabilities[54]. - Total liabilities decreased from CNY 894,598,007.27 to CNY 801,717,897.38, a reduction of about 10.4%[108]. - Current liabilities decreased from CNY 583,452,993.03 to CNY 446,507,406.87, a decrease of approximately 23.5%[108]. Research and Development - The company plans to enhance its R&D capabilities by focusing on eight major therapeutic areas, including anti-tumor and cardiovascular drugs[28]. - Research and development expenses increased by 17.52% to ¥14.25 million, attributed to the separate accounting of R&D expenses from certain subsidiaries during the reporting period[51]. - The company is continuing its research on the sodium cantharidate series products and expanding the potential of ethnic medicinal materials, with ongoing projects to upgrade quality standards for various traditional Chinese medicines[44]. - The company aims to develop a new profit growth point by selecting ethnic medicinal varieties for secondary research and development, targeting products with potential sales exceeding ¥100 million[45]. Market and Sales Strategy - The company has established a comprehensive sales network covering most regions of the country, with a focus on a specialized sales team and a unique marketing management model[29]. - The company has established a product-based marketing team to ensure sustainable market development, focusing on professional terminal promotions and exploring e-commerce sales platforms as a supplement[30]. - Prescription drug sales are primarily conducted through a model of "agent cooperation + professional academic promotion + self-built marketing team," covering most provinces in China[30]. - The pharmaceutical manufacturing revenue accounted for 60.58% of total operating revenue, while the pharmaceutical commercial revenue accounted for 39.42%[27]. Risk Management - The report includes a risk statement regarding forward-looking statements, indicating that future plans do not constitute a substantive commitment to investors[5]. - The company faces risks from potential public health emergencies that could lead to a significant decline in product sales, as seen during the COVID-19 pandemic[62]. - The company is actively monitoring industry policy changes, such as the new Drug Administration Law and price control measures, which could impact profitability[64]. - The company has established a dynamic warning mechanism to adapt to regulatory changes and improve its operational strategies accordingly[64]. - The company faces risks of profit margin squeeze due to upstream raw material price increases, which cannot be passed down to downstream drug prices[72]. Corporate Governance - There were no plans for profit distribution or capital reserve transfer to increase share capital during the reporting period[4]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[6]. - The report has not been audited, but the management has guaranteed its accuracy and completeness[7]. - The company continues to employ Lixin Accounting Firm for the 2020 audit, as approved by the 2019 annual general meeting[80]. - The actual controllers and major shareholders have maintained a good integrity record without administrative or criminal penalties during the reporting period[81]. Social Responsibility - The company donated approximately ¥4.5 million worth of medical supplies to support the fight against COVID-19 in Hubei province and an additional ¥1.01 million for poverty alleviation efforts in Guizhou province[43]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 51,326[93]. - The top shareholder, Guizhou Shenqi Investment Co., Ltd., holds 131,301,620 shares, accounting for 24.59% of total shares[96]. - Guizhou Maijisi Investment Management Co., Ltd. holds 88,001,946 shares, representing 16.48% of total shares[96]. - Zhang Zhijun holds 40,007,750 shares, which is 7.49% of total shares[96]. Accounting Policies - The financial statements are prepared in accordance with the Chinese Accounting Standards and reflect the company's financial position, operating results, and cash flows accurately[153]. - The company uses Renminbi as its accounting currency[156]. - The company applies the first-in, first-out (FIFO) method for inventory valuation upon issuance[186]. - The company recognizes long-term equity investments using the cost method for subsidiaries and the equity method for joint ventures and associates[194].